keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunoglobulin

keyword
https://www.readbyqxmd.com/read/28525399/allergen-immunotherapy-for-the-treatment-of-respiratory-allergies-in-the-elderly
#1
Gyu-Young Hur, Ji-Ho Lee, Hae-Sim Park
PURPOSE OF REVIEW: Respiratory allergies, including asthma and allergic rhinitis can also occur in the elderly. Allergen immunotherapy for allergic diseases is the only disease-modifying treatment for patients with allergies available thus far. Here, we review current evidence supporting the use of allergen immunotherapy in the elderly and discuss its efficacy and utility for the treatment of respiratory allergic diseases in this setting. RECENT FINDINGS: Subcutaneous and/or sublingual immunotherapy are effective therapeutic options in not only young but also older patients...
May 17, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28522011/vaccination-with-a-live-attenuated-acinetobacter-baumannii-deficient-in-thioredoxin-provides-protection-against-systemic-acinetobacter-infection
#2
Sarah Ainsworth, Patrick M Ketter, Jieh-Juen Yu, Rose C Grimm, Holly C May, Andrew P Cap, James P Chambers, M Neal Guentzel, Bernard P Arulanandam
Multi-drug resistant Acinetobacter baumannii (MDR-Ab), an opportunistic pathogen associated with nosocomial and combat related infections, has a high mortality due to its virulence and limited treatment options. Deletion of the thioredoxin gene (TrxA) from a clinical isolate of MDR-Ab resulted in a 100-fold increase in 50% lethal dose (LD50) in a systemic challenge murine model. Thus, we investigated the potential use of this attenuated strain as a live vaccine against MDR-Ab. Mice were vaccinated by subcutaneous (s...
May 15, 2017: Vaccine
https://www.readbyqxmd.com/read/28504465/effects-of-sa237-a-humanized-anti-interleukin-6-receptor-monoclonal-antibody-on-pre-and-postnatal-development-in-cynomolgus-monkey
#3
Ryuichi Katagiri, Kana Ishihara-Hattori, Werner Frings, Jun Amano, Antje Fuchs, Shuichi Chiba
BACKGROUND: SA237 is a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody in which the constant and variable regions have been engineered for a longer plasma half-life. According to literature, blocking of IL-6 related functions could have an influence on pregnancy sustainment, development of the immune system, and brain growth. METHODS: SA237 effects on dams, embryo-fetal development, parturition and postnatal development were investigated in an enhanced pre- and postnatal development study, in which SA237 was subcutaneously administered to pregnant cynomolgus monkeys at dose levels of 2 or 50 mg/kg once weekly from gestation day 20 until parturition...
May 15, 2017: Birth Defects Res
https://www.readbyqxmd.com/read/28502133/t-regulatory-cells-response-to-allergen-specific-immunotherapy-in-patients-with-allergic-airway-diseases-a-prospective-study
#4
Raghdaa A Ramadan, Emad A Morad, Mohamed El-Shabrawy
Forkhead box P3 (FoxP3) T regulatory (Treg) cells modulate the immune system by blocking other types of T-cells. They maintain tolerance to self-antigens and help in inducing tolerance to foreign antigens. A deregulation of FoxP3 Tregs seems to play an important role in allergic disorders. The aim of this work was to study the response of FoxP3 Treg cells and their FoxP3 expression in patients, attending the Allergy Unit and the Chest Outpatient Clinic, Faculty of Medicine, Zagazig University, with allergic airway diseases, before and 1 year after receiving subcutaneous allergen specific immunotherapy (SIT)...
June 2016: Egyptian Journal of Immunology
https://www.readbyqxmd.com/read/28480635/drug-induced-cutaneous-lupus-erythematosus-after-immunoglobulin-treatment-in-chronic-inflammatory-demyelinating-polyneuropathy-a-case-series
#5
Max E Adrichem, Markus V Starink, Ester Mm van Leeuwen, Christine Kramer, Ivo N van Schaik, Filip Eftimov
We describe six patients with cutaneous lupus erythematosus (cLE) during immunoglobulin G (IgG) treatment. Five patients were diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) and one patient with possible CIDP. Five patients received intravenous immunoglobulin (IVIg) and one patient subcutaneous immunoglobulin (SCIg). Skin lesions were systematically assessed by a dermatologist including skin biopsies. Patients showed disseminated erythematous plaques on several parts of the body with predominance of the chest and face...
May 8, 2017: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/28467615/management-of-patients-with-malignancies-and-secondary-immunodeficiencies-treated-with-immunoglobulins-in-clinical-practice-long-term-data-of-the-signs-study
#6
Marcel Reiser, Michael Borte, Dörte Huscher, Ulrich Baumann, David Pittrow, Claudia Sommer, Martin Stangel, Maria Fasshauer, Ralf Gold, Manfred Hensel
OBJECTIVE: We aimed to describe the current management and outcomes of patients with secondary immunodeficiencies (SID) on intravenous (IV) or subcutaneous (SC) immune-globulins (IG) as maintenance therapy to prevent infections. METHODS: Non-interventional, prospective study (average follow-up 20.5 months). RESULTS: Of the 307 SID patients (mean age 63.7 ± 14.4 years, 52% males, in 31% IG newly initiated), 95.4% received IV (mean dosing interval 4...
May 3, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28460848/subcutaneous-abdominal-abscesses-in%C3%A2-a-patient-with-common-variable%C3%A2-immunodeficiency-receiving-subcutaneous-immunoglobulin-therapy
#7
Thatchai Kampitak, Stephen D Betschel
No abstract text is available yet for this article.
April 28, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28453837/borrelia-burgdorferi-bbi39-paralogs-targets-of-protective-immunity-reduce-pathogen-persistence-either-in-hosts-or-in-the-vector
#8
Preeti Singh, Deepshikha Verma, Brian T Backstedt, Simarjot Kaur, Manish Kumar, Alexis A Smith, Kavita Sharma, Xiuli Yang, José F Azevedo, Maria Gomes-Solecki, Ozlem Buyuktanir, Utpal Pal
Borrelia burgdorferi genome harbors several paralogous gene families (pgf) that can encode immunogenic proteins of unknown function. Protein-protein interaction assays using a transmission-blocking vaccine candidate, BBA52, as bait identified an interacting partner in spirochetes-a member of pgf 54, annotated as BBI39. We show that BBI39 is a surface-exposed membrane antigen that is immunogenic during spirochete infection, despite the gene being primarily transcribed in the vector with a transient expression in the host only at tick-bite sites...
March 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28444082/ii-brazilian-consensus-on-the-use-of-human-immunoglobulin-in-patients-with-primary-immunodeficiencies
#9
Ekaterini Simões Goudouris, Almerinda Maria do Rego Silva, Aluce Loureiro Ouricuri, Anete Sevciovic Grumach, Antonio Condino-Neto, Beatriz Tavares Costa-Carvalho, Carolina Cardoso de Mello Prando, Cristina Maria Kokron, Dewton de Moraes Vasconcelos, Fabíola Scancetti Tavares, Gesmar Rodrigues Silva Segundo, Irma Cecília Douglas Paes Barreto, Mayra de Barros Dorna, Myrthes Anna Maragna Toledo Barros, Wilma Carvalho Neves Forte
In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010...
2017: Einstein
https://www.readbyqxmd.com/read/28437791/early-introduction-of-subcutaneous-hepatitis-b-immunoglobulin-following-liver-transplantation-for-hepatitis-b-virus-infection-a-prospective-multicenter-study-erratum
#10
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Transplantation
https://www.readbyqxmd.com/read/28398628/population-pharmacokinetics-and-target-engagement-of-natalizumab-in-patients-with-multiple-sclerosis
#11
Kumar Kandadi Muralidharan, Geoffrey Kuesters, Tatiana Plavina, Meena Subramanyam, Daniel D Mikol, Sreeja Gopal, Ivan Nestorov
Natalizumab (humanized immunoglobulin G4 antibody targeting alpha-4 integrins) is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS) that has been in clinical use since 2006. However, natalizumab pharmacokinetic (PK) characteristics and concentration alpha-4 integrin saturation relationships have not been well described in the scientific literature. Therefore, clinical data from 11 studies were pooled and analyzed to characterize the PK and pharmacodynamic (PD) properties of natalizumab in RRMS subjects...
April 11, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28370285/identification-and-characterization-of-a-nationwide-danish-adult-common-variable-immunodeficiency-cohort
#12
Lena Westh, Trine Hyrup Mogensen, Lars Skov Dalgaard, Jens Magnus Bernth Jensen, Terese Katzenstein, Ann-Brit Eg Hansen, Olav Ditlevsen Larsen, Steen Terpling, Thyge Lynghøj Nielsen, Carsten Schade Larsen
In this study we identified all adults living in Denmark diagnosed with common variable immunodeficiency (CVID) and characterized them according to clinical presentation and EUROclass classification. Using a retrospective, cross-sectional design, possible CVID patients were identified in the Danish National Patient Register and Centers in Denmark treating patients with primary immunodeficiencies. The CVID diagnosis was verified by review of medical records. One-hundred-seventy-nine adults with CVID were identified...
April 2, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28345437/clinical-profile-dosing-and-quality-of-life-outcomes-in-primary-immune-deficiency-patients-treated-at-home-with-immunoglobulin-g-data-from-the-ideal-patient-registry
#13
Sean Kearns, Loretta Kristofek, William Bolgar, Luqman Seidu, Samantha Kile
BACKGROUND: Patients with primary immune deficiency (PID) often require immunoglobulin G (IgG, commonly referred to as Ig) replacement therapy to prevent infections and associated comorbidities. Ig therapy can be given either through intravenous or subcutaneous routes, and both can be done in the home setting. There is limited information available on the real-world diagnosis, management, and outcomes of this patient population, given the variable disease presentation and treatment options...
April 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28345260/resistance-training-and-aerobic-training-improve-muscle-strength-and-aerobic-capacity-in-chronic-inflammatory-demyelinating-polyneuropathy
#14
Lars H Markvardsen, Kristian Overgaard, Karen Heje, Søren H Sindrup, Ingelise Christiansen, John Vissing, Henning Andersen
INTRODUCTION: We investigated the effects of aerobic and resistance exercise in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Eighteen CIDP patients treated with subcutaneous immunoglobulin performed 12 weeks of aerobic exercise and 12 weeks of resistance exercise after a run-in period of 12 weeks without exercise. Three times weekly the participants performed aerobic exercise on an ergometer bike or resistance exercise with unilateral training of knee and elbow flexion/extension...
March 27, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/28343601/effects-of-rg7652-a-monoclonal-antibody-against-pcsk9-on-ldl-c-ldl-c-subfractions-and-inflammatory-biomarkers-in-patients-at-high-risk-of-or-with-established-coronary-heart-disease-from-the-phase-2-equator-study
#15
Amos Baruch, Sofia Mosesova, John D Davis, Nageshwar Budha, Alexandr Vilimovskij, Robert Kahn, Kun Peng, Kyra J Cowan, Laura Pascasio Harris, Thomas Gelzleichter, Josh Lehrer, John C Davis, Whittemore G Tingley
RG7652 (MPSK3169A), a fully human immunoglobulin G1 (IgG1) monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), blocks the interaction between PCSK9 and low-density lipoprotein (LDL) receptor. EQUATOR (ClinicalTrials.govNCT01609140), a randomized, double-blind, and dose-ranging phase 2 study, evaluated RG7652 in patients (1) at high risk for or (2) with coronary heart disease (CHD). The primary end point was change in LDL cholesterol (LDL-C) from baseline to day 169. Patients (n = 248; median age, 64 years; 57% men; 52% with established CHD; 82% on statins) with baseline LDL-C levels of 90 to 250 mg/dl (mean, 126 mg/dl) continuing on standard-of-care therapy were randomized to receive 1 of 5 RG7652 doses or placebo, subcutaneously every 4, 8, or 12 weeks for 24 weeks...
March 1, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28321436/pneumococcal-antibody-titers-a-comparison-of-patients-receiving-intravenous-immunoglobulin-versus-subcutaneous-immunoglobulin
#16
Pamella F Abghari, Pavadee Poowuttikul, Elizabeth Secord
Purpose: Immunoglobulin replacement is the mainstay treatment in patients with humoral immunodeficiencies, yet a handful of patients continue to develop sinopulmonary infections while on therapy. The objective of our study was to compare immunoglobulin G (IgG) pneumococcal antibody levels in patients with humoral immune deficiencies who have been on intravenous immunoglobulin (IVIG) replacement for at least 1 year to those on subcutaneous immunoglobulin (SCIG) therapy for at least 1 year. Methods: A retrospective chart review was completed on 28 patients...
2017: Global Pediatric Health
https://www.readbyqxmd.com/read/28320129/immunoglobulin-therapy-in-the-treatment-of-multifocal-motor-neuropathy
#17
REVIEW
Aditya Kumar, Huned S Patwa, Richard J Nowak
Multifocal motor neuropathy (MMN) is a chronic immune-mediated disorder leading to slowly progressive muscle weakness and wasting. Current treatments are aimed at modulating the immune system in order to avoid further decline and to maintain functional status. Intravenous immunoglobulin (IVIg) is widely used in the treatment of immune-mediated disorders and is the only treatment approved for MMN. While patients do remain stable with maintenance IVIg treatment, most patients will slowly deteriorate over many years...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28295417/subcutaneous-versus-intravenous-immunoglobulin-for-chronic-autoimmune-neuropathies
#18
EDITORIAL
Elie Naddaf, M Hassan Murad, P James B Dyck
No abstract text is available yet for this article.
March 10, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/28292255/subcutaneous-igg-in-the-myositis-spectrum-disorders
#19
Maria Giovanna Danieli, Chiara Gelardi, Veronica Pedini, Francesco Logullo, Armando Gabrielli
The efficacy of subcutaneous immunoglobulin is reported in several neurological disorders and, more recently, its use has been extended to other inflammatory diseases, such as the idiopathic inflammatory myopathies, including polymyositis and dermatomyositis. Due to the rarity of these disorders, the role of immunoglobulin, administered intravenously or subcutaneously, remains unclear and poorly investigated. We report our experience about the use of subcutaneous immunoglobulin in myositis spectrum disorders, from idiopathic inflammatory myopathies to more complex conditions, such as overlap and cancer-associated myositis or pregnancy...
March 14, 2017: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/28274526/efficacy-of-long-term-omalizumab-therapy-in-patients-with-severe-asthma
#20
Junko Saji, Takahito Yamamoto, Motonaka Arai, Masamichi Mineshita, Teruomi Miyazawa
BACKGROUND: The efficacy of omalizumab, an anti-immunoglobulin E (IgE) antibody, has been studied in patients with severe bronchial asthma. We conducted a study to evaluate, on the basis of both objective and subjective measures, the efficacy of omalizumab as a long-term therapy in patients with severe and persistent asthma. METHODS: Omalizumab was administered subcutaneously every two or four weeks. The results of pulmonary function tests, Asthma Control Test (ACT) and Asthma Health Questionnaire (AHQ)-33 scores, the dosage of methylprednisolone during the 12-month treatment period, and the number of emergency visits prior to the start of treatment with omalizumab were compared in patients pre- and post-treatment with omalizumab...
March 2017: Respiratory Investigation
keyword
keyword
54047
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"